source
- AstraZeneca outlines restructuring as earnings show cost cuts, while Alnylam slides and Regeneron posts record quarterAstraZeneca said it will redeploy resources through a new restructuring program aimed at cutting costs while staying on track to hit its long‑term revenue goal of $80 billion by 2030. The company h…
- U.S. Health Care System's Economics Are Broken, Says Ascendiun CEOPaul Markovich, president and CEO of Ascendiun, argues that the economics of the United States health care system are fundamentally broken. He recounts meeting a healthy, active man in his early 6…